Seminars in Hematology
Volume 45 , Pages S2-S6 , July 2008

Treatment of Follicular Non-Hodgkin's Lymphoma: The Old and the New

  • Jonathan W. Friedberg

      Affiliations

    • Corresponding Author InformationAddress correspondence to Jonathan W. Friedberg, MD, Associate Professor of Medicine and Oncology, University of Rochester, 601 Elmwood Ave, Box 704, Rochester, NY 14612

References 

  1. Fisher RI, Kaminski MS, Wahl RL, Knox SJ, Zelenetz AD, Vose JM, et al. Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. J Clin Oncol. 2005;23:7565–7573
  2. Halaas JL, Teruya-Feldstein J, Filippa DA, Chaya M, Naresh KN, Zelenetz AD. The Follicular Lymphoma International Prognostic Index (FLIPI) Is superior to WHO/REAL histological grade for identifying high-risk patients: A retrospective review of the MSKCC experience in 260 patients with follicular lymphoma. Blood. 2004;104:892a;(abstr 3268)
  3. Solal-Celigny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, et al. Follicular lymphoma international prognostic index. Blood. 2004;104:1258–1265
  4. Buske C, Hoster E, Dreyling M, Hasford J, Unterhalt M, Hiddemann W. The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood. 2006;108:1504–1508
  5. An observational study of treatment, outcomes, and prognosis in patients with follicular non-Hodgkin's lymphoma. http://clinicaltrials.gov/ct2/show/NCT00097565Accessed January 22, 2008
  6. Link BK, Cerhan JR, Dillon H, Farber CM, Feliciano S, Friedberg JW, et al. Prospective validation of the FLIPI: Baseline distribution and correlates in newly diagnosed follicular lymphoma (FL) patients from the US: First report of the National Lympho-Care Study. Blood. 2005;106:293a;(abstr 1000)
  7. Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005;106:3725–3732
  8. Hiddemann W, Forstpointner R, Kneba M, Schmitz N, Schmits R, Metner B, et al. The addition of rituximab to combination chemotherapy with CHOP has a long lasting impact on subsequent treatment in remission in follicular lymphoma but not in mantle cell lymphoma: Results of two prospective randomized studies of the German Low Grade Lymphoma Study Group (GLSG). Blood. 2004;104:50a;(abstr)
  9. Foussard C, Mounier N, Van Hoof A, Delwail V, Casasnovas O, Deconinck E, et al. Update of the FL2000 randomized trial combining rituximab to CHVP-Interferon in follicular lymphoma (FL) patients (pts). J Clin Oncol. 2006;24:7508;(abstr)
  10. Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood. 2005;105:1417–1423
  11. Marcus RE, Solal-Celigny P, Imrie K, Cunningham D, Flores E, Catalano J, et al. MabThera (rituximab) plus cyclophosphamide, vincristine and prednisone (CVP) chemotherapy improves survival in previously untreated patients with advanced follicular non-Hodgkins lymphoma (NHL). Blood. 2006;108:146a;(abstr 481)
  12. Herold M, Haas A, Srock S, Neser S, Al Ali K, Neubauer A, et al. Addition of rituximab to first-line MCP (mitoxantrone, chlorambucil, prednisolone) chemotherapy prolongs survival in advanced follicular lymphoma—4 year follow-up results of a phase III trial of East German Study Group Hematology and Oncology (OSHO#39). Blood. 2006;108:147a;(abstr 484)
  13. Friedberg JW, Huang J, Dillon H, Farber C, Feliciano S, Hainsworth J, et al. Initial therapeutic strategy in follicular lymphoma (FL): An analysis from the National LymphoCare Study (NLCS). Proc Am Soc Clin Oncol. 2006;24:428s;(abstr 7527)
  14. Rituximab in treating patients with low tumor burden indolent non-Hodgkin's lymphoma. http://clinicaltrials.gov/ct2/show/NCT00075946Accessed January 22, 2008
  15. Primary rituximab and maintenance. http://clinicaltrials.gov/ct2/show/NCT00140582Accessed January 22, 2008
  16. Combination chemotherapy with monoclonal antibody therapy in treating patients with newly diagnosed non-Hodgkin's lymphoma. http://clinicaltrials.gov/ct2/show/NCT00006721Accessed January 22, 2008
  17. Hainsworth JD, Litchy S, Shaffer DW, Lackey VL, Grimaldi M, Greco FA. Maximizing therapeutic benefit of rituximab: Maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma—A randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol. 2005;23:1088–1095
  18. Rohatiner AZ, Nadler L, Davies AJ, Apostolidis J, Neuberg D, Matthews J, et al. Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up. J Clin Oncol. 2007;25:2554–2559
  19. Horning SJ, Younes A, Jain V, Kroll S, Lucas J, Podoloff D, et al. Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J Clin Oncol. 2005;23:712–719
  20. Witzig TE, Flinn IW, Gordon LI, Emmanouilides C, Czuczman MS, Saleh MN, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol. 2002;20:3262–3269
  21. Friedberg JW, Cohen P, Chen L, Robinson KS, Forero-Torres A, La Casce AS, et al. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: Results from a phase II multicenter, single-agent study. J Clin Oncol. 2008;26:204–210
  22. Demo SD, Kirk CJ, Aujay MA, Buchholz TJ, Dajee M, Ho MN, et al. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res. 2007;67:6383–6391
  23. Ahn KS, Sethi G, Chao TH, Neuteboom ST, Chaturvedi MM, Palladino MA, et al. Salinosporamide A (NPI-0052) potentiates apoptosis, suppresses osteoclastogenesis, and inhibits invasion through down-modulation of NF-kappaB regulated gene products. Blood. 2007;110:2286–2295
  24. Chauhan D, Velankar M, Brahmandam M, Hideshima T, Podar K, Richardson P, et al. A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma. Oncogene. 2007;26:2374–2380
  25. O'Connor OA, Wright J, Moskowitz C, Muzzy J, MacGregor-Cortelli B, Stubblefield M, et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol. 2005;23:676–684
  26. O'Connor OA. Marked clinical activity of the proteasome inhibitor bortezomib in patients with follicular and mantle-cell lymphoma. Clin Lymphoma Myeloma. 2005;6:191–199
  27. Leonard JP, Furman RR, Coleman M. Proteasome inhibition with bortezomib: A new therapeutic strategy for non-Hodgkin's lymphoma. Int J Cancer. 2006;119:971–979
  28. Stewart KA. Phase I evaluation of carfilzomib (PR-171) in hematological malignancies: Responses in multiple myeloma and Waldenstrom's macroglobulinemia at well-tolerated doses. J Clin Oncol. 2007;25:441s;(abstr 8003)
  29. De Vos S, Dakhil SR, McLaughlin P, Saleh MN, Belt R, Flowers C, et al. Phase 2 study of bortezomib weekly or twice weekly plus rituximab in patients with follicular (FL) or marginal zone (MZL) lymphoma: Final results. Blood. 2006;108:208a;(abstr 694)
  30. Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer. 2004;4:314–322
  31. Witzig TE, Vose J, Pietronigro D, Takeshita K, Ervin-Haynes A, Zeldis J, et al. Preliminary results from a phase II study of lenalidomide oral monotherapy in relapsed/refractory indolent non-Hodgkin. J Clin Oncol. 2007;25:457s;(abstr 8066)
  32. Ghobrial IM, Witzig TE, Adjei AA. Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin. 2005;55:178–194
  33. Goy A. New directions in the treatment of mantle cell lymphoma: An overview. Clin Lymphoma Myeloma 7 Suppl. 2006;1:S24–S32
  34. Ramanarayanan J, Hernandez-Ilizaliturri FJ, Chanan-Khan A, Czuczman MS. Pro-apoptotic therapy with the oligonucleotide Genasense (oblimersen sodium) targeting Bcl-2 protein expression enhances the biological anti-tumour activity of rituximab. Br J Haematol. 2004;127:519–530
  35. Chanan-Khan A. Bcl-2 antisense therapy in hematologic malignancies. Curr Opin Oncol. 2004;16:581–585
  36. Chanan-Khan A. Bcl-2 antisense therapy in B-cell malignancies. Blood Rev. 2005;19:213–221
  37. Goy A, Ford P, Feldman T, Pecora A, Goldberg S, Donato M, et al. A phase 1 trial of the pan Bcl-2 family inhibitor obatoclax mesylate (GX15-070) in combination with bortezomib in patients with relapsed/refractory mantle cell lymphoma. Blood. 2007;110:757a;(abstr 2569)
  38. Wilson WH, Tulpule A, Levine AM, Dunleavy K, Krivoshik AP, Hagey A, et al. A phase 1/2a study evaluating the safety, pharmacokinetics, and efficacy of ABT-263 in subjects with refractory or relapsed lymphoid malignancies. Blood. 2007;110:412a;(abstr 1371)
  39. Blagosklonny MV. How Avastin potentiates chemotherapeutic drugs: action and reaction in antiangiogenic therapy. Cancer Biol Ther. 2005;4:1307–1310

 STATEMENT OF CONFLICT OF INTEREST: Research support/Principal Investigator: Cephalon, Millennium; Consultant/Scientific Advisory Board: Genentech.

PII: S0037-1963(08)00119-4

doi: 10.1053/j.seminhematol.2008.07.003

Seminars in Hematology
Volume 45 , Pages S2-S6 , July 2008

Article Tools